$RGLS
Regulus Therapeutics Inc.

2023 Q4 Form 10-Q Financial Statement

#000162828023038295 Filed on November 09, 2023

View on sec.gov

Income Statement

Concept 2023 Q4 2023 Q3
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $2.537M $2.637M
YoY Change 14.33% 17.04%
% of Gross Profit
Research & Development $5.707M $5.488M
YoY Change 21.76% 3.35%
% of Gross Profit
Depreciation & Amortization $76.00K $51.00K
YoY Change 130.3% 59.38%
% of Gross Profit
Operating Expenses $8.300M $8.125M
YoY Change 19.73% 7.43%
Operating Profit -$8.125M
YoY Change 7.43%
Interest Expense $239.0K $137.0K
YoY Change 74.45% -21.71%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$8.061M -$7.824M
YoY Change 18.63% 3.62%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$8.061M -$7.824M
YoY Change 18.63% 3.62%
Net Earnings / Revenue
Basic Earnings Per Share -$0.40
Diluted Earnings Per Share -$0.40 -$0.40
COMMON SHARES
Basic Shares Outstanding 20.22M shares 19.48M shares
Diluted Shares Outstanding 19.63M shares

Balance Sheet

Concept 2023 Q4 2023 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $23.77M $30.78M
YoY Change -39.31% -32.08%
Cash & Equivalents $23.77M $25.83M
Short-Term Investments $0.00 $4.949M
Other Short-Term Assets $4.412M $1.228M
YoY Change -10.31% 25.69%
Inventory
Prepaid Expenses $3.010M $3.010M
Receivables
Other Receivables
Total Short-Term Assets $28.18M $35.08M
YoY Change -36.07% -28.94%
LONG-TERM ASSETS
Property, Plant & Equipment $1.061M $1.008M
YoY Change 97.95% 96.49%
Goodwill
YoY Change
Intangibles $33.00K $36.00K
YoY Change -46.77% -46.27%
Long-Term Investments
YoY Change
Other Assets $0.00
YoY Change
Total Long-Term Assets $2.571M $2.665M
YoY Change -2.5% -3.23%
TOTAL ASSETS
Total Short-Term Assets $28.18M $35.08M
Total Long-Term Assets $2.571M $2.665M
Total Assets $30.75M $37.75M
YoY Change -34.18% -27.59%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $204.0K $599.0K
YoY Change 16.57% -24.75%
Accrued Expenses $691.0K $620.0K
YoY Change -28.1% 0.81%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $1.334M $2.128M
YoY Change -70.43% -52.48%
Total Short-Term Liabilities $8.508M $8.248M
YoY Change -27.01% -21.6%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $1.055M $1.240M
YoY Change
Total Long-Term Liabilities $1.055M $1.240M
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $8.508M $8.248M
Total Long-Term Liabilities $1.055M $1.240M
Total Liabilities $9.563M $9.488M
YoY Change -28.77% -23.83%
SHAREHOLDERS EQUITY
Retained Earnings -$513.2M -$505.2M
YoY Change 6.22% 6.04%
Common Stock $534.4M $533.4M
YoY Change 3.47% 3.36%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $21.19M $28.26M
YoY Change
Total Liabilities & Shareholders Equity $30.75M $37.75M
YoY Change -34.18% -27.59%

Cashflow Statement

Concept 2023 Q4 2023 Q3
OPERATING ACTIVITIES
Net Income -$8.061M -$7.824M
YoY Change 18.63% 3.62%
Depreciation, Depletion And Amortization $76.00K $51.00K
YoY Change 130.3% 59.38%
Cash From Operating Activities -$6.125M -$6.273M
YoY Change -2.05% -6.83%
INVESTING ACTIVITIES
Capital Expenditures $71.00K $542.0K
YoY Change 12.7% -18166.67%
Acquisitions
YoY Change
Other Investing Activities $5.003M -$4.899M
YoY Change -52.49% -61.9%
Cash From Investing Activities $4.932M -$5.441M
YoY Change -52.88% -57.69%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -873.0K 289.0K
YoY Change -93.56%
NET CHANGE
Cash From Operating Activities -6.125M -6.273M
Cash From Investing Activities 4.932M -5.441M
Cash From Financing Activities -873.0K 289.0K
Net Change In Cash -2.066M -11.43M
YoY Change -149.03% -24.36%
FREE CASH FLOW
Cash From Operating Activities -$6.125M -$6.273M
Capital Expenditures $71.00K $542.0K
Free Cash Flow -$6.196M -$6.815M
YoY Change -1.9% 1.26%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2253000 usd
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
8125000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
13697000 usd
us-gaap Operating Expenses
OperatingExpenses
22809000 usd
us-gaap Operating Expenses
OperatingExpenses
21307000 usd
us-gaap Interest Expense
InterestExpense
490000 usd
us-gaap Interest Expense
InterestExpense
492000 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-21975000 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-21527000 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1000 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1000 usd
us-gaap Net Income Loss
NetIncomeLoss
-21976000 usd
us-gaap Net Income Loss
NetIncomeLoss
-21528000 usd
us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
0 usd
us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
-31000 usd
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.19
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
14969574 shares
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
14969574 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
18535209 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
18535209 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
14727591 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
14727591 shares
CY2022Q2 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.1
CY2022Q2 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.1
CY2023Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000 shares
CY2023Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000 shares
CY2023Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
20222672 shares
CY2023Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
20222672 shares
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
16840261 shares
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
16840261 shares
CY2023Q3 us-gaap Common Stock Value
CommonStockValue
20000 usd
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
17000 usd
CY2023Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
533386000 usd
CY2022Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
516457000 usd
CY2023Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
0 usd
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-12000 usd
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-505152000 usd
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-483176000 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
28259000 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
33291000 usd
CY2023Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
37747000 usd
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
46716000 usd
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5488000 usd
CY2022Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5310000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
15389000 usd
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2637000 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
7420000 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
7610000 usd
CY2022Q3 us-gaap Operating Expenses
OperatingExpenses
7563000 usd
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-8125000 usd
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-7563000 usd
us-gaap Interest And Other Income
InterestAndOtherIncome
1324000 usd
us-gaap Interest And Other Income
InterestAndOtherIncome
272000 usd
CY2023Q3 us-gaap Interest Expense
InterestExpense
137000 usd
CY2022Q3 us-gaap Interest Expense
InterestExpense
175000 usd
CY2023Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-7824000 usd
CY2022Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-7551000 usd
CY2023Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2022Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-7824000 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-7551000 usd
CY2023Q3 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
0 usd
CY2022Q3 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
5000 usd
CY2023Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-7824000 usd
CY2022Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-7546000 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-21976000 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-21559000 usd
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.40
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.40
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.50
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.50
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.19
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.46
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.46
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
19628815 shares
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
19628815 shares
CY2023Q1 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
21000 usd
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
410000 usd
CY2023Q1 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Before Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentBeforeTaxPortionAttributableToParent
12000 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-7139000 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
26595000 usd
CY2023Q2 rgls Stock Issued During Period Value Stock Issued From Private Placement Net Of Offering Costs
StockIssuedDuringPeriodValueStockIssuedFromPrivatePlacementNetOfOfferingCosts
14003000 usd
CY2023Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
30000 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-7013000 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
33997000 usd
CY2023Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
1089000 usd
CY2023Q3 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
24000 usd
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
973000 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-7824000 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
28259000 usd
CY2022Q1 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
2000 usd
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1000000 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-6719000 usd
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
49241000 usd
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
420000 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-7258000 usd
CY2022Q2 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Before Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentBeforeTaxPortionAttributableToParent
-36000 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
42367000 usd
CY2022Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
4488000 usd
CY2022Q3 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
1000 usd
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
360000 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-7551000 usd
CY2022Q3 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Before Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentBeforeTaxPortionAttributableToParent
5000 usd
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
39670000 usd
us-gaap Net Income Loss
NetIncomeLoss
-21976000 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
151000 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
89000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
1765000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
1780000 usd
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
-107000 usd
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
-52000 usd
us-gaap Other Operating Activities Cash Flow Statement
OtherOperatingActivitiesCashFlowStatement
113000 usd
us-gaap Other Operating Activities Cash Flow Statement
OtherOperatingActivitiesCashFlowStatement
101000 usd
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-619000 usd
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-802000 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
424000 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
511000 usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-411000 usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-217000 usd
rgls Increase Decrease In Accrued Research And Development Expenses
IncreaseDecreaseInAccruedResearchAndDevelopmentExpenses
-459000 usd
rgls Increase Decrease In Accrued Research And Development Expenses
IncreaseDecreaseInAccruedResearchAndDevelopmentExpenses
271000 usd
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-68000 usd
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-319000 usd
rgls Operating Lease Right Of Use And Lease Liabilities Net Gain Loss
OperatingLeaseRightOfUseAndLeaseLiabilitiesNetGainLoss
-63000 usd
rgls Operating Lease Right Of Use And Lease Liabilities Net Gain Loss
OperatingLeaseRightOfUseAndLeaseLiabilitiesNetGainLoss
-46000 usd
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
-631000 usd
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
-665000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-20643000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-19273000 usd
us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
4899000 usd
us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
30289000 usd
us-gaap Proceeds From Sale Maturity And Collection Of Shortterm Investments
ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments
15000000 usd
us-gaap Proceeds From Sale Maturity And Collection Of Shortterm Investments
ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments
5000000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
542000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
298000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
9559000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-25587000 usd
us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
14004000 usd
us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
0 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
1163000 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
4491000 usd
CY2023Q3 us-gaap Restricted Cash
RestrictedCash
62000 usd
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
25895000 usd
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
20076000 usd
us-gaap Interest Paid Net
InterestPaidNet
375000 usd
us-gaap Interest Paid Net
InterestPaidNet
348000 usd
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
1000 usd
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
1000 usd
us-gaap Noncash Or Part Noncash Acquisition Fixed Assets Acquired1
NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1
71000 usd
us-gaap Noncash Or Part Noncash Acquisition Fixed Assets Acquired1
NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1
0 usd
rgls Financingfrom Sale Proceeds Debt Agreement Revenues
FinancingfromSaleProceedsDebtAgreementRevenues
557600000 usd
CY2023Q3 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
30800000 usd
us-gaap Use Of Estimates
UseOfEstimates
Use of EstimatesOur condensed financial statements are prepared in accordance with GAAP, which requires us to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses and the disclosure of contingent assets and liabilities in our financial statements and accompanying notes. An estimated loss contingency is accrued in our financial statements if it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. Although these estimates are based on our knowledge of current events and actions we may undertake in the future, actual results may ultimately differ from these estimates and assumptions.
CY2023Q3 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
4950000 usd
CY2023Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
0 usd
CY2023Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
33225055 shares
CY2023Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
1000 usd
CY2023Q3 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
4949000 usd
CY2022Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
14944000 usd
CY2022Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
0 usd
CY2022Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
12000 usd
CY2022Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
14932000 usd
CY2023Q3 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
30240000 usd
CY2022Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
36422000 usd
rgls Number Of Amendments
NumberOfAmendments
10 amendment
CY2023Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
20222672 shares
CY2023Q3 rgls Common Stock Voting Rights Votes
CommonStockVotingRightsVotes
1 vote
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
6222000 shares
CY2023Q3 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
34157000 shares
CY2023Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
973000 usd
CY2022Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
360000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1765000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1780000 usd
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
196000 usd
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
800000 usd
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
824000 usd
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
277000 usd
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
2097000 usd
CY2023Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
161000 usd
CY2023Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
1936000 usd
CY2023Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
696000 usd
CY2023Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1240000 usd

Files In Submission

Name View Source Status
FilingSummary.xml Edgar Link unprocessable
rgls-20230930_pre.xml Edgar Link unprocessable
0001628280-23-038295-index-headers.html Edgar Link pending
0001628280-23-038295-index.html Edgar Link pending
0001628280-23-038295.txt Edgar Link pending
0001628280-23-038295-xbrl.zip Edgar Link pending
ex-311x20230930.htm Edgar Link pending
ex-312x20230930.htm Edgar Link pending
ex-321x20230930.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
rgls-20230930.htm Edgar Link pending
rgls-20230930.xsd Edgar Link pending
Show.js Edgar Link pending
rgls-20230930_cal.xml Edgar Link unprocessable
rgls-20230930_def.xml Edgar Link unprocessable
rgls-20230930_lab.xml Edgar Link unprocessable
rgls-20230930_htm.xml Edgar Link completed